Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Preference for injectable over oral HIV pre-exposure prophylaxis in public-sector primary-care clinics in Swaziland

Siedner, Mark J.a,b,c,d; Hettema, Anitae; Hughey, Allisone; Oldenburg, Catherine E.f; Kohler, Stefang; Bärnighausen, Kateg; McMahon, Shannong,h; Jia, Chuang; Lejeune, Charlottee; Matse, Sindyi; Bärnighausen, Tilld,g

doi: 10.1097/QAD.0000000000001859
Research Letters
Buy
SDC

Long-acting injectable (LAI) HIV pre-exposure prophylaxis (PrEP) may mitigate adherence challenges reported by young women in Southern Africa. We assessed preferences for PrEP in public-sector, primary care clinics in Swaziland. Among surveyed respondents, 75% (95% confidence interval = 65–83%) stated preference for LAI over oral PrEP; with no differences by sex, age, or sexual behavior (all P > 0.05). Notably, over 70% (95% confidence interval 58–82%) with current use of oral PrEP also stated preference for LAI PrEP.

aMassachusetts General Hospital

bHarvard Medical School, Boston, Massachusetts, USA

cMbarara University of Science and Technology, Mbarara, Uganda

dAfrica Health Research Institute, KwaZulu-Natal, South Africa

eClinton Health Access Initiative, Mbabane, Swaziland

fUniversity of California San Francisco, San Francisco, California, USA

gUniversity of Heidelberg, Heidelberg, Germany

hJohns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA

iSwaziland Ministry of Health, Mbababane, Swaziland.

Correspondence to Mark J. Siedner, MD, MPH, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. E-mail: msiedner@mgh.harvard.edu

Received 4 April, 2018

Revised 18 April, 2018

Accepted 18 April, 2018

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com).

Copyright © 2018 Wolters Kluwer Health, Inc.